Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

JANX013

Other · developed by Janux Therapeutics

Phase 1 Most advanced trial
JANX Developer
1 Registered trials

What is JANX013?

JANX013 is an agent administered intravenously. It is studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Janux Therapeutics (JANX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07813637 Phase 1 Prostate Cancer Recruiting JANX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-Resistant Prostate Cancer (CRPC)Metastatic Castration-Resistant Prostate Cancer PatientsMetastatic Prostate CancerProstate Cancer

More from Janux Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JANX page.

Follow JANX, the company behind JANX013

See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JANX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.